Woojung Bio Inc
215380
Company Profile
Business description
Woojung Bio Inc is engaged in the research and development of natural science and engineering. The company operates in bio business and infection control business. The new drug development cluster is established to provide customized data for rapid efficacy evaluation, safety evaluation, and analysis testing required for new drug development. The infection control business is a virtuous cycle business that implements space sterilization and infection prevention facilities in hospitals and other special facilities.
Contact
593-8 Dongtan Giheung-ro
Yeongcheon-dong, Woojung Bio New Drug Cluster
Gyeonggi-do
Hwaseong-si
KORT: +82 312805200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
142
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
Despite an earnings downgrade, shares in FLT remain undervalued.
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,399.27 | 32.34 | -0.38% |
| DAX 40 | 24,786.01 | 208.82 | -0.84% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,487.16 | 42.73 | -0.41% |
| HKSE | 22,684.09 | 392.82 | -1.70% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,357.49 | 0.73 | -0.01% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |